Literature DB >> 7295552

Serum and urine concentrations of 5-methoxypsoralen after oral administration.

L M Stolk, W Westerhof, R H Cormane, P A van Zwieten.   

Abstract

Serum and urine concentrations were measured after oral administration of 5-methoxypsoralen (0.6 mg/kg or I.2 mg/kg) to psoriasis patients. A dose of 0.6 mg/kg resulted in low serum concentrations, but after I.2 mg/kg, much higher serum concentrations were reached. There was much individual variation in the time required for reaching peak serum levels. Minute amounts of unchanged 5-methoxypsoralen were excreted in urine. Much larger amounts were excreted as conjugates.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295552     DOI: 10.1111/j.1365-2133.1981.tb00772.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects.

Authors:  Maria Magdalena Quetglas-Llabrés; Cristina Quispe; Jesús Herrera-Bravo; Marcelo D Catarino; Olívia R Pereira; Susana M Cardoso; Kamal Dua; Dinesh Kumar Chellappan; Kavita Pabreja; Saurabh Satija; Meenu Mehta; Antoni Sureda; Miquel Martorell; Dinara Satmbekova; Balakyz Yeskaliyeva; Javad Sharifi-Rad; Naeem Rasool; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-04-25       Impact factor: 7.310

2.  The clastogenic effect of 5-methoxypsoralen plus UV-A in human lymphocytes in vitro and its modification by the anticlastogen beta-aminoethylisothiouronium.

Authors:  G Abel; A Mannschedel
Journal:  Hum Genet       Date:  1987-06       Impact factor: 4.132

3.  Peak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration.

Authors:  P Humbert; P Treffel; S Makki; J Millet; P Agache
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 4.  5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of methoxsalen and other psoralens.

Authors:  F A de Wolff; T V Thomas
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

6.  Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.

Authors:  F Aubin; S Makki; P Humbert; P Muret; P Agache
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

7.  Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.

Authors:  P Muret; P Humbert; S Makki; P Bechtel; S Urien; J P Tillement
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

8.  Food-induced increase in bioavailability of 5-methoxypsoralen.

Authors:  H Ehrsson; I Wallin; A M Ros; S Eksborg; M Berg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.